5TLR

Solution NMR structure of gHwTx-IV

  • Classification: TOXIN
  • Organism(s): Haplopelma schmidti
  • Mutation(s): Yes 

  • Deposited: 2016-10-11 Released: 2017-02-22 
  • Deposition Author(s): Agwa, A.J., Schroeder, C.I.
  • Funding Organization(s): National Health and Medical Research Council (NHMRC, Australia)

Experimental Data Snapshot

  • Method: SOLUTION NMR
  • Conformers Calculated: 50 
  • Conformers Submitted: 20 
  • Selection Criteria: all calculated structures submitted 

wwPDB Validation   3D Report Full Report


This is version 1.3 of the entry. See complete history


Literature

Spider peptide toxin HwTx-IV engineered to bind to lipid membranes has an increased inhibitory potency at human voltage-gated sodium channel hNaV1.7.

Agwa, A.J.Lawrence, N.Deplazes, E.Cheneval, O.Chen, R.M.Craik, D.J.Schroeder, C.I.Henriques, S.T.

(2017) Biochim Biophys Acta 1859: 835-844

  • DOI: 10.1016/j.bbamem.2017.01.020
  • Primary Citation of Related Structures:  
    5TLR

  • PubMed Abstract: 
  • The human voltage-gated sodium channel sub-type 1.7 (hNa V 1.7) is emerging as an attractive target for the development of potent and sub-type selective novel analgesics with increased potency and fewer side effects than existing therapeutics. HwTx-IV, a spider derived peptide toxin, inhibits hNa V 1 ...

    The human voltage-gated sodium channel sub-type 1.7 (hNa V 1.7) is emerging as an attractive target for the development of potent and sub-type selective novel analgesics with increased potency and fewer side effects than existing therapeutics. HwTx-IV, a spider derived peptide toxin, inhibits hNa V 1.7 with high potency and is therefore of great interest as an analgesic lead. In the current study we examined whether engineering a HwTx-IV analogue with increased ability to bind to lipid membranes would improve its inhibitory potency at hNa V 1.7. This hypothesis was explored by comparing HwTx-IV and two analogues [E1PyrE]HwTx-IV (mHwTx-IV) and [E1G,E4G,F6W,Y30W]HwTx-IV (gHwTx-IV) on their membrane-binding affinity and hNa V 1.7 inhibitory potency using a range of biophysical techniques including computational analysis, NMR spectroscopy, surface plasmon resonance, and fluorescence spectroscopy. HwTx-IV and mHwTx-IV exhibited weak affinity for lipid membranes, whereas gHwTx-IV showed improved affinity for the model membranes studied. In addition, activity assays using SH-SY5Y neuroblastoma cells expressing hNa V 1.7 showed that gHwTx-IV has increased activity at hNa V 1.7 compared to HwTx-IV. Based on these results we hypothesize that an increase in the affinity of HwTx-IV for lipid membranes is accompanied by improved inhibitory potency at hNa V 1.7 and that increasing the affinity of gating modifier toxins to lipid bilayers is a strategy that may be useful for improving their potency at hNa V 1.7.


    Organizational Affiliation

    Institute for Molecular Bioscience, The University of Queensland, Qld 4072, Australia. Electronic address: s.henriques@uq.edu.au.



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Mu-theraphotoxin-Hs2aA36Haplopelma schmidtiMutation(s): 4 
UniProt
Find proteins for P83303 (Cyriopagopus schmidti)
Explore P83303 
Go to UniProtKB:  P83303
Protein Feature View
Expand
  • Reference Sequence
Experimental Data & Validation

Experimental Data

  • Method: SOLUTION NMR
  • Conformers Calculated: 50 
  • Conformers Submitted: 20 
  • Selection Criteria: all calculated structures submitted 
  • OLDERADO: 5TLR Olderado

Structure Validation

View Full Validation Report




Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
National Health and Medical Research Council (NHMRC, Australia)AustraliaAPP1080405

Revision History  (Full details and data files)

  • Version 1.0: 2017-02-22
    Type: Initial release
  • Version 1.1: 2017-03-01
    Changes: Database references
  • Version 1.2: 2017-09-27
    Changes: Author supporting evidence, Structure summary
  • Version 1.3: 2020-01-08
    Changes: Author supporting evidence, Data collection